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Abstract 
Diffuse chronic sclerosingosteomyelitis (DCSO) is a refractory disease, becausethe etiology and pathogenesis re-
main poorly understood and to determine the border betweenunhealthy boneandhealthybone is difficult. However, 
progressive inflammation, clinical symptoms and a high recurrence rate of DCSO were the reasons for surgical 
treatment. We report a case of a 66-year old woman with DCSO of the right side of mandible who was treated with 
hemimandibulectomy and simultaneous reconstruction by vascularized free fibula flap. After preoperative adminis-
tration of minocycline for 1 month, the bone fluorescence was successfully monitored by using a Visually Enhan-
ced Lesion Scope (VELscope®). Intraoperatively, we could determine the resection boundaries. We investigated 
the clinical and histopathological findings. The fluorescence findings were well correlated with histopathological 
findings. Using a VELscope®was handy and useful to determine the border between DCSO lesion andhealthybone.
The free fibula flap under the minocycline-derived bone fluorescence by using a VELscope®offered a good quality 
of mandibular bone and the successful management of an advanced and refractory DCSO.
Key words: Fluorescence-guided bone resection, fibular free flap, osteomyelitis of the mandible, diffuse chroni-
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Introduction
Diffuse chronic sclerosingosteomyelitis (DCSO) of the 
jaw, first described by Marzola (1,2), results from an 
immunologic reaction to microbial stimuli, such as bac-
terial toxins and infection, but this hypothesis was not 
supported by bacteriologic and histologic findings. The 
management of DCSO thus remains challenging (3). 
Although a variety of conventional treatments have been 
tried for DCSO, and a small proportion of patients have 
had long-term relief of symptoms, most cases ofDCSO 
are refractory to treatment. Once the disease process be-
comes chronic, the general consensus is that the most 
effective treatment for DCSO of the jaw is a combina-
tion of antimicrobial therapy and surgical debridement. 
However, the treatment often requires several protracted 
courses of antibiotics and multiple surgical interven-
tions, becausethe etiology and pathogenesis remain po-
orly understood (4,5). However, currently, the surgical 
therapy is only loosely standardized for the patients who 
are refractory to several conservative treatments. On the 
other hand, these surgical treatments are controversial, 
because even after the aggressive surgical treatment it 
may become worse. One of the reasons is the difficul-
ty to define the margins of the unhealthy bone more 
precisely, because no suitable imaging modalities exist 
to determine the resection area and the excision of the 
lesion is insufficient and then would be recurrence. To 
date, intraoperatively, it is not possible to visualize this 
feature more easily, and no successful surgical treatment 
protocols have been published. Therefore, we consi-
dered that determination of the border betweenhealthy 
boneand unhealthybone was important. Minocycline, a 
tetracyclineantibiotic, is incorporated in healthy bone 
and has the effect of inducing visual fluorescence reten-
tion. Due to this incorporation, it can be detected by its 
fluorescence (6). To date, tetracycline bone fluorescence 
has been introduced as the surgical therapy of several 
bone diseases in some hospital facilities (7). We then 
reported our successful experience with a patient who 
underwent surgical treatment with radical resection of 
the hemimandible including the condyle with immediate 
reconstruction with a free fibula flap under minocycline 
bone fluorescence imaging by Visually Enhanced Le-
sion Scope (VELscope®). The histopathological inves-
tigation ofthe fluorescence area of the resected specimen 
was also shown. 
Case Report  
Fluorescence guided bone resection was performed after 
written informed consent in the female patient. A 66-
year-old female was referred to the Department of Oral 
and Maxillofacial Surgery, Kyushu Dental University 
Hospital, with a pain and swelling around the mandi-
bularangleon the right side, which firstly occurred two 
years before and presented with history of recurrent pain 
and swelling over the right side of mandible. The patient 
reported endodontic treatment on the right lower second 
molar and chemotherapy of antibiotics were performed 
about 1 month ago by a general dentist, but it failed to 
improve the symptoms. The panoramic radiography 
showed change in bone density in the region of the ill-
defined osteosclerotic change of the right mandible (�ig. 
1A). Computed tomography of the mandible showed 
localized widening and sclerosis of the right hemiman-
dible (Fig. 1B,C) and bone scintigram (technetium 99m) 
showed enhanced uptake in only the right side of the 
mandible (Fig. 1D). 
Fig. 1. Panoramic radiography A) and Computed tomography B,C) 
show bone sclerosis with scattered osteolysis of the ascending ramus. 
Technetium 99m bonescintigram D) shows enhanced uptake in only 
the right part of the mandible.
Preoperatively, this patient received minocycline 100 
mg twice a day for 1 month. Using a VELscope® (LED 
Dental Inc., Burnaby, BC, Canada), a certified medical 
device (no. 41315446) approved by the American Den-
tal Association for the detection of mucosal tissue ab-
normalities (CDT D0431), minocycline-derived bone 
fluorescence was visualized intraoperatively under blue 
excitation. In this surgical approach, hemimandibulec-
tomy was conducted under fluorescence guidance (�ig. 
2. A-D). Surgical treatment consisted of a complete re-
section of the right ascending ramus of the mandible, 
including the condyle, and immediate reconstruction 
with a microsurgically anastomosed fibula flap from the 
left side. Postoperative healing was uneventful without 
major functional or aesthetic impairment. The patient 
showed normal mouth opening and a standard occlusion. 
There was no relevant donor site morbidity. A postope-
rative panoramic radiograph showed the reconstructed 
ascending ramus to be in the correct position. The cli-
nical and radiographic follow-up showed no signs of a 
recurrence.
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Fig. 2. Intraoperative clinical picture A) after subperiosteal explora-
tion. The extent of the unhealthy bone became obvious by use of 
VELscope® B) (arrowhead: Detected area show healthy bone. ar-
row: Undetected area show unhealthy bone) Intraoperative clinical 
picture of resected section C) and fluorescence picture D) after fluo-
rescence-guided bone resection.
Fig. 3. Clinical picture and fluorescence picture of the postoperative 
resected mandible A). VELscope® findings of the resected mandible 
B). Histopathological findings of the following section; a and b C-F). 
(sectiona; C and E, section b; D and �,  C,D; ×40 magnification, E,�; 
×100 magnification).
We showed the macroscopic findings and the VELsco-
pe® findings of the resected mandible and compared 
with each findings (�ig. 3A,B). The histopathological 
findings of the region of fluorescent positive showed 
healthy bone covered withthickcortical bone tissue 
and consisted of age-appropriate fatty marrow without 
inflammation, fibrosis, norhyperemia. Additionally, 
there were lining of a few intact osteoblasts and osteo-
cytes in healthy bone (Fig. 3C,E). On the other hand, 
postoperative histopathological findings of the chronic 
sclerosingosteomyelitis lesion; non-fluorescence area 
showed littlecompact bonetissuein thesubstantial por-
tion of cortical bone per low-power field (�ig. 3D) and 
dense, irregular bony trabeculae bordered by an active 
layer of osteoblasts and intermingled fibrous tissue with 
mild lymphocytic infiltration per high-power field (�ig. 
3�). The non-fluorescent moietyand the DCSO lesions 
hadhistopathological correlations. Additionally, micro-
biologic culture from the biopsy specimen was negative 
for microorganisms. 
Discussion
Despite the development of various new antibiotics and 
anti-inflammatory drugs, DCSO of the mandible often 
does not respond to medical treatment (8-10). Because 
recurrent symptoms may persist for years, still some 
patients require surgical resection of the mandible. 
Although demarcation of unhealthy bone is of crucial 
importance in the therapy of the DCSO of the jaw, at 
present, no effective and no useful modalities allow the 
precise intraoperative identification of affected bone. 
Indeed, if the unhealthy bone area can be undetected, 
residual unhealthy bone results in a progression of the 
osteomyelitis or recurrence of DCSO.
VELscope®is a reusable light source that emits a cone 
of light in the blue spectrum (400-460 nm) into the oral 
cavity, causing fluorophores in the oral tissue to excite 
and fluoresce. In particular, VELscope® has been wi-
dely used in the diagnosis of precancerous lesions, such 
as leukoplakia, carcinoma in situ or squamous cell car-
cinoma of the oral cavity using autofluorescence ima-
ging (11). On the other hand, tetracycline bone labeling 
is a diagnostic tool routinely applied to address diverse 
questions of bone metabolism at the microscopic level 
(12).  However, to our knowledge, there are few reports 
about the intraoperative use of macroscopic tetracycline 
fluorescence imaging of healthy versus unhealthy bone 
in patients with DCSO. This is the report to investigate 
about DCSO histopathologically and discuss the effica-
cy of the VELscope® (13). 
In this case, the typical fluorescence pattern in osteo-
myelitis showed a really weak signal in the cortical 
bone. Due to this new bone formation, tetracycline in-
corporation is evident in the respective regions resulting 
in the typical fluorescence pattern. The histopathological 
findings confirmed that the non-fluorescent moietywas-
closely correlated with the DCSO lesions.VELscope®is 
a suitable tool to visualize areas of the unhealthy bone 
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by visual fluorescence loss in patients with DCSO. As 
demonstrated, visual fluorescence loss in the unhealthy 
areas of the bone is useful as a guide for fluorescence-
guided bone resection with relevant clinical interpre-
tation. Generally, surgical procedures are indicated in 
almost all patients with DCSO who show resistance to 
the conventional treatment with antibiotics. Using the 
VELscope®device, excellent results can be reached re-
garding complete resection of unhealthy bone areas, and 
postoperative outcome after wound closure and wound 
healing. 
The most commonly affected regions with osteomyeli-
tis of the mandible include the angle and body of the 
mandible (14). The occurrence has been reduced since 
the advent of antibiotics and improved dental hygiene. 
Currently, patients at risk of developing osteomyelitis 
of the mandible including those who have undergone 
radiotherapy to the head and neck region, are immuno-
compromised, are heavy smokers and drinkers, are on 
immunosuppressive therapy, or suffer from uncontrolled 
diabetes (9,14). The most common presenting symptoms 
include facial swelling, pain, trismus andhypoesthesia of 
mentum. Once the disease process has been present for a 
month and is refractory to conventional treatments, such 
as oral antibiotics, it is termed chronic. Once the disease 
process becomes chronic, the general consensus is that 
the most effective treatment for chronic osteomyelitis 
of the mandible is a combination of antimicrobial the-
rapy and surgical debridement (15). However, the ma-
nagement often requires several protracted courses of 
antibiotics, at least 1 hospital admission, and multiple 
surgical interventions.
We reported our successful experience with a patient 
who underwent surgical treatment with radical resection 
of the hemimandible including the condyle with imme-
diate reconstruction with a free fibula flap under mino-
cycline bone fluorescence imaging by VELscope®. We 
recommend the minocycline-derived bone fluorescence 
by using a VELscope® thatis a valuable and useful te-
chniqueto distinguish healthy bone from unhealthy bone 
in the treatment of refractory DCSO. Microvascular 
reconstruction with a fibular free flap under the mino-
cycline-derived bone fluorescence technique by using a 
VELscope® should be considered as a treatment option 
in the management of DCSO of the mandible because of 
the consistency with thehistopathologicalfindings.
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